Possibly, I believe we could benefit from a restructure.
The business is now at a stage where separate business units with defined responsibilities and management could be a significant benefit and provide greater focus going forward.
I could see three separate units each requiring different management skill sets:
1 - Research
2 - Manufacturing
3 - Commercial operations
Stem Cell Therapy advancements, page-435
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.005(1.35%) |
Mkt cap ! $78.49M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.5¢ | 36.5¢ | $32.14K | 86.68K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 65604 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 12.55pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
37.5¢ |
Change
0.005 ( 1.35 %) |
||||
| Open | High | Low | Volume | ||
| 37.0¢ | 38.0¢ | 37.0¢ | 21015 | ||
| Last updated 12.55pm 10/05/2024 ? | |||||
| OCC (ASX) Chart |